Latest news

• Eli Lilly focuses on 2022 launches as revenues climb by 18%

  US-based Lilly recorded worldwide revenue of $6.77bn in Q3, including worldwide revenue of $423.5m for COVID-19 therapies. ... Excluding revenue from COVID-19 therapies, revenue growth was 11% in both third-quarter and year-to-date 2021 results.

• Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

  Swiss-based Novartis has announced 'solid Q3 growth' of 5% compared to the same period last year, with innovative medicines up by 7%. ... Net sales topped $13bn for Q3; top earners were Entresto with $924m – which saw 'continued strong growth' and

• AZ is expecting late-stage COVID-19 vaccine data this year

  AZ reiterated the aim for a data readout later this year in its Q3 results released today, although the company also said that this timeline depends on the rate of infection ... Elsewhere in AZ’s Q3 results, the British drugmaker beat sales estimates

• Keytruda growth helps Merck to offset COVID-19 impact in Q3

  Profits beat expectations in the third quarter of 2020. Merck (MSD) has raised its full-year earnings forecast after posting higher-than-expected profits in its third quarter results yesterday. ... said Ken Frazier, chief executive officer of Merck in

• Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

  During an earnings call for the company’s third quarter results, Pfizer’s chief executive officer Albert Bourla said a data monitoring committee has not yet conducted any interim efficacy analysis